The bacterial ghost platform system: Production and applications

Bioengineered Bugs

Volumn 1, Issue 5, 2010, Pages 326-336

  Langemann, Timo ^a,b   Koller, Verena Juliana ^a,b   Muhammad, Abbas ^b   Kudela, Pavol ^a,c   Mayr, Ulrike Beate ^a   Lubitz, Werner ^a,b  

^a BIRD C GmbH and CoKEG   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

Bacterial ghosts; Bacterial inactivation; Drug carrier; E mediated lysis; Fermentation; Tumor treatment; Vaccines; White biotechnology

Indexed keywords

ADJUVANT; BACTERIAL DNA; DNA VACCINE; DRUG CARRIER; ENDONUCLEASE; PROPIOLACTONE;

BACTERIAL GROWTH; BACTERIAL MEMBRANE; BACTERIOLYSIS; BATCH FERMENTATION; BIOTECHNOLOGY; DOWNSTREAM PROCESSING; DRUG DELIVERY SYSTEM; FREEZE DRYING; QUALITY CONTROL; REVIEW;

BACTERIA (MICROORGANISMS); NEGIBACTERIA;

EID: 78449290476     PISSN: 19491018     EISSN: 19491026     Source Type: Journal    
DOI: 10.4161/bbug.1.5.12540     Document Type: Review

References (93)

1. Hutchinson III CA, Sinsheimer RL. The process of infection with bacteriophage phiX174. X. Mutations in a phiX174 lysis gene. J Mol Biol 1966; 18:429-47.
2. Henrich B, Lubitz W, Plapp R. Lysis of Escherichia coli by induction of cloned phiX174 genes. Mol Gen Genet 1982; 185:493-7.
3. Young KD, Young R. Lytic action of cloned phiX174 gene E. J Virol 1982; 44:993-1002.
4. Barrell BG, Air GM, Hutchison CA, 3rd. Overlapping genes in bacteriophage phiX174. Nature 1976; 264:34-41.
5. Pollock TJ, Tessman ES, Tessman I. Identification of lysis protein E of bacteriophage phiX174. J Virol 1978; 28:408-10.
6. Denhardt DT, Sinsheimer RL. The process of infection with bacteriophage phi-X174. 3. Phage maturation and lysis after synchronized infection. J Mol Biol 1965; 12:641-6.
7. Markert A, Zillig W. Studies on the lysis of Escherichia coli C by bacteriophage PhiX174. Virology 1965; 25:88-97.
8. Bläsi U, Linke RP, Lubitz W. Evidence for membranebound oligomerization of bacteriophage phiX174 lysis protein-E. J Biol Chem 1989; 264:4552-8.
9. Witte A, Lubitz W. Biochemical characterization of phiX174-protein-E-mediated lysis of Escherichia coli. Eur J Biochem 1989; 180:393-8.
10. Bläsi U, Geisen R, Lubitz W, Henrich B, Plapp R. Localisation of the bacteriophage phiX174 lysis gene product in the cell envelope of Escherichia coli. Berlin & New York: de Gruyter 1983.
11. Halfmann G, Leduc M, Lubitz W. Different sensitivity of autolytic deficient Escherichia coli mutants to the mode of induction. FEMS Microbiology Letters 1984; 24:205-8.
12. Halfmann G, Lubitz W. Differential induction of Escherichia coli autolysis by penicillin and the bacteriophage phi X174 gene E product. J Bacteriol 1986; 166:683-5.
13. Lubitz W, Pugsley AP. Changes in host cell phospholipids composition of phiX174 gene E product. FEMS Microbiology Letters 1985; 30:171-5.
14. Bayer ME. Areas of adhesion between wall and membrane of Escherichia coli. J Gen Microbiol 1968; 53:395-404.
15. Witte A, Lubitz W, Bakker EP. Proton-motive-forcedependent step in the pathway to lysis of Escherichia coli induced by bacteriophage phi X174 gene E product. J Bacteriol 1987; 169:1750-2.
16. Witte A, Wanner G, Blasi U, Halfmann G, Szostak M, Lubitz W. Endogenous transmembrane tunnel formation mediated by phiX174 lysis protein E. J Bacteriol 1990; 172:4109-14.
17. Witte A, Wanner G, Sulzner M, Lubitz W. Dynamics of phiX174 protein E-mediated lysis of Escherichia coli. Arch Microbiol 1992; 157:381-8.
18. Bläsi U, Henrich B, Lubitz W. Lysis of Escherichia coli by cloned phiX174 gene E depends on its expression. J Gen Microbiol 1985; 131:1107-14.
19. Lubitz W, Halfmann G, Plapp R. Lysis of Escherichia coli after infection with phiX174 depends on the regulation of the cellular autolytic system. J Gen Microbiol 1984; 130:1079-87.
20. Witte A, Brand E, Mayrhofer P, Narendja F, Lubitz W. Mutations in cell division proteins FtsZ and FtsA inhibit phiX174 protein-E-mediated lysis of Escherichia coli. Arch Microbiol 1998; 170:259-68.
21. Witte A, Wanner G, Lubitz W, Holtje JV. Effect of phi X174 protein E-mediated lysis on murein composition of Escherichia coli. FEMS Microbiol Lett 1998; 164:149-57.
22. Bernhardt TG, Roof WD, Young R. Genetic evidence that the bacteriophage phi X174 lysis protein inhibits cell wall synthesis. Proc Natl Acad Sci USA 2000; 97:4297-302.
23. Schön P, Schrot G, Wanner G, Lubitz W, Witte A. Two-stage model for integration of the lysis protein E of phiX174 into the cell envelope of Escherichia coli. FEMS Microbiol Rev 1995; 17:207-12.
24. Jalava K, Hensel A, Szostak M, Resch S, Lubitz W. Bacterial ghosts as vaccine candidates for veterinary applications. J Control Release 2002; 85:17-25.
25. Lubitz W, Witte A, Eko FO, Kamal M, Jechlinger W, Brand E, et al. Extended recombinant bacterial ghost system. J Biotechnol 1999; 73:261-73.
26. Halfmann G, Gotz F, Lubitz W. Expression of bacteriophage PhiX174 lysis gene E in Staphylococcus carnosus TM300. FEMS Microbiol Lett 1993; 108:139-43.
27. Jalava K, Eko FO, Riedmann E, Lubitz W. Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert Rev Vaccines 2003; 2:45-51.
28. Lubitz P, Mayr UB, Lubitz W. Applications of bacterial ghosts in biomedicine. Austin: Landes Bioscience 2009.
29. Riedmann EM, Kyd JM, Cripps AW, Lubitz W. Bacterial ghosts as adjuvant particles. Expert Rev Vaccines 2007; 6:241-53.
30. Szostak M, Lubitz W. Recombinant bacterial ghosts as multivaccine vehicles. New York: Cold Spring Harbor Laboratory Press 1991.
31. Szostak M, Wanner G, Lubitz W. Recombinant bacterial ghosts as vaccines. Res Microbiol 1990; 141:1005-7.
32. Ebensen T, Paukner S, Link C, Kudela P, de Domenico C, Lubitz W, et al. Bacterial ghosts are an efficient delivery system for DNA vaccines. J Immunol 2004; 172:6858-65.
33. Mayr UB, Koller VJ, Lubitz P, Lubitz W. Bacterial ghosts as vaccine and drug delivery platforms. In: ed. Sleator R, Hill C ed. Patho-Biotechnology. Austin, TX: Landes Bioscience, 2008:50-9.
34. Mayr UB, Walcher P, Azimpour C, Riedmann E, Haller C, Lubitz W. Bacterial ghosts as antigen delivery vehicles. Adv Drug Deliv Rev 2005; 57:1381-91.
35. Paukner S, Stiedl T, Kudela P, Bizik J, Al Laham F, Lubitz W. Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery. Expert Opin Drug Deliv 2006; 3:11-22.
36. Walcher P, Mayr UB, Azimpour-Tabrizi C, Eko FO, Jechlinger W, Mayrhofer P, et al. Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors. Expert Rev Vaccines 2004; 3:681-91.
37. Jechlinger W, Glocker J, Haidinger W, Matis A, Szostak MP, Lubitz W. Modulation of gene expression by promoter mutants of the lambdacI857/pRM/pR system. J Biotechnol 2005; 116:11-20.
38. Jechlinger W, Szostak MP, Witte A, Lubitz W. Alteredtemperature induction sensitivity of the lambda pR/cI857 system for controlled gene E expression in Escherichia coli. FEMS Microbiol Lett 1999; 173:347-52.
39. Haidinger W, Szostak MP, Jechlinger W, Lubitz W. Online monitoring of Escherichia coli ghost production. Appl Environ Microbiol 2003; 69:468-74.
40. Haidinger W, Szostak MP, Beisker W, Lubitz W. Green fluorescent protein (GFP)-dependent separation of bacterial ghosts from intact cells by FACS. Cytometry 2001; 44:106-12.
41. Haidinger W, Mayr UB, Szostak MP; Resch S; Lubitz W. Escherichia coli ghost production by expression of lysis gene E and Staphylococcal nuclease. Appl Environ Microbiol 2003; 69:6106-13.
42. Perrin P, Morgeaux S. Inactivation of DNA by betapropiolactone. Biologicals 1995; 23:207-11.
43. Hensel A, van Leengoed LA, Szostak M, WindtH, Weissenbock H, Stockhofe-Zurwieden N, et al. Induction of protective immunity by aerosol or oral application of candidate vaccines in a dose-controlled pig aerosol infection model. J Biotechnol 1996; 44:171-81.
44. Hensel A, Stockhofe-Zurwieden N, Petzoldt K, Lubitz W. Oral immunization of pigs with viable or inactivated Actinobacillus pleuropneumoniae serotype 9 induces pulmonary and systemic antibodies and protects against homologous aerosol challenge. Infect Immun 1995; 63:3048-53.
45. Huter V, Hensel A, Brand E, Lubitz W. Improved protection against lung colonization by Actinobacillus pleuropneumoniae ghosts: characterization of a genetically inactivated vaccine. J Biotechnol 2000; 83:161-72.
46. Hensel A, Huter V, Katinger A, Raza P, Strnistschie C, Roesler U, et al. Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state. Vaccine 2000; 18:2945-55.
47. Marchart J, Dropmann G, Lechleitner S, Schlapp T, Wanner G, Szostak MP, et al. Pasteurella multocidaand Pasteurella haemolytica-ghosts: new vaccine candidates. Vaccine 2003; 21:3988-97.
48. Marchart J, Rehagen M, Dropmann G, Szostak MP, Alldinger S, Lechleitner S, et al. Protective immunity against pasteurellosis in cattle, induced by Pasteurella haemolytica ghosts. Vaccine 2003; 21:1415-22.
49. Eko FO, Schukovskaya T, Lotzmanova EY, Firstova VV, Emalyanova NV, Klueva SN, et al. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine 2003; 21:3663-74.
50. Hobom G, Arnold N, Ruppert A. OmpA fusion proteins for presentation of foreign antigens on the bacterial outer membrane. Dev Biol Stand 1995; 84:255-62.
51. Huter V, Szostak MP, Gampfer J, Prethaler S, Wanner G, Gabor F, et al. Bacterial ghosts as drug carrier and targeting vehicles. J Control Release 1999; 61:51-63.
52. Kennedy EP. Osmotic regulation and the biosynthesis of membrane-derived oligosaccharides in Escherichia coli. Proc Natl Acad Sci USA 1982; 79:1092-5.
53. Kuen B, Sara M, Lubitz W. Heterologous expression and self-assembly of the S-layer protein SbsA of Bacillus stearothermophilus in Escherichia coli. Mol Microbiol 1996; 19:495-503.
54. Truppe M, Howorka S, Schroll G, Lechleitner S, Kuen B, Resch S, et al. Biotechnological applications of recombinant S-layer proteins rSbsA and rSbsB from Bacillus stearothermophilus PV72. FEMS Microbiol Rev 1997; 20:88-98.
55. Howorka S, Sara M, Wang Y, Kuen B, Sleytr UB, Lubitz W, et al. Surface-accessible residues in the monomeric and assembled forms of a bacterial surface layer protein. J Biol Chem 2000; 275:37876-86.
56. Riedmann EM, Kyd JM, Smith AM, Gomez-Gallego S, Jalava K, Cripps AW, et al. Construction of recombinant S-layer proteins (rSbsA) and their expression in bacterial ghosts-a delivery system for the nontypeable Haemophilus influenzae antigen Omp26. FEMS Immunol Med Microbiol 2003; 37:185-92.
57. Paukner S, Kohl G, Lubitz W. Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells. J Control Release 2004; 94:63-74.
58. Paukner S, Kohl G, Jalava K, Lubitz W. Sealed bacterial ghosts-novel targeting vehicles for advanced drug delivery of water-soluble substances. J Drug Target 2003; 11:151-61.
59. Hatfaludi T, Liska M, Zellinger D, Ousman JP, Szostak M, Ambrus A, et al. Bacterial ghost technology for pesticide delivery. J Agric Food Chem 2004; 52:5627-34.
60. Gentschev I, Dietrich G, Spreng S, Kolb-Maurer A, Brinkmann V, Grode L, et al. Recombinant attenuated bacteria for the delivery of subunit vaccines. Vaccine 2001; 19:2621-8.
61. Jager E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, et al. Recombinant vaccinia/fowipox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA 2006; 103:14453-8.
62. Medina E, Guzman CA. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 2001; 19:1573-80.
63. Mengesha A, Dubois L, Chiu RK, Paesmans K, Wouters BG, Lambin P, et al. Potential and limitations of bacterial-mediated cancer therapy. Front Biosci 2007; 12:3880-91.
64. + T cells by bacterial vector. Blood 2008; 111:1404-12.
65. Reschel T, Konak C, Oupicky D, Seymour LW, Ulbrich K. Physical properties and in vitro transfection efficiency of gene delivery vectors based on complexes of DNA with synthetic polycations. J Control Release 2002; 81:201-17.
66. Schnell S, Young JW, Houghton AN, Sadelain M. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells. J Immunol 2000; 164:1243-50.
67. Schumacher L, Ribas A, Dissette VB, McBride WH, Mukherji B, Economou JS, et al. Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother 2004; 27:191-200.
68. Weiner DB. Introduction to DNA vaccines issue. Vaccine 2006; 24:4459-60.
69. Liu MA, Wahren B, Karlsson Hedestam GB. DNA vaccines: recent developments and future possibilities. Hum Gene Ther 2006; 17:1051-61.
70. Wiendl H, Hohlfeld R, Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 2005; 26:373-80.
71. Paukner S, Kudela P, Kohl G, Schlapp T, Friedrichs S, Lubitz W. DNA-loaded bacterial ghosts efficiently mediate reporter gene transfer and expression in macrophages. Mol Ther 2005; 11:215-23.
72. Lubitz W. Bacterial ghosts as carrier and targeting systems. Expert Opin Biol Ther 2001; 1:765-71.
73. Kudela P, Paukner S, Mayr UB, Cholujova D, Kohl G, Schwarczova Z, et al. Effective gene transfer to melanoma cells using bacterial ghosts. Cancer Lett 2007.
74. Kudela P, Paukner S, Mayr UB, Cholujova D, Schwarczova Z, Sedlak J, et al. Bacterial ghosts as novel efficient targeting vehicles for DNA delivery to the human monocyte-derived dendritic cells. J Immunother 2005; 28:136-43.
75. Kudela P, Paukner S, Mayr UB, Cholujova D, Kohl G, Schwarczova Z, et al. Effective gene transfer to melanoma cells using bacterial ghosts. Cancer Lett 2008; 262:54-63.
76. Trombetta ES, Ebersold M, Garrett W, Pypaert M, Mellman I. Activation of lysosomal function during dendritic cell maturation. Science 2003; 299:1400-3.
77. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005; 23:975-1028.
78. Mayrhofer P, Tabrizi CA, Walcher P, Haidinger W, Jechlinger W, Lubitz W. Immobilization of plasmid DNA in bacterial ghosts. J Control Release 2005; 102:725-35.
79. Jechlinger W, Azimpour Tabrizi C, Lubitz W, Mayrhofer P. Minicircle DNA immobilized in bacterial ghosts: in vivo production of safe non-viral DNA delivery vehicles. J Mol Microbiol Biotechnol 2004; 8:222-31.
80. Chen ZY, He CY, Kay MA. Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther 2005; 16:126-31.
81. Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. Adv Genet 2005; 54:3-20.
82. Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. Hum Mol Genet 1992; 1:363-9.
83. Yu M, Finn OJ. DNA vaccines for cancer too. Cancer Immunol Immunother 2006; 55:119 30.
84. Brady MS, Lee F, Petrie H, Eckels DD, Lee JS. CD4(+) T cells kill HLA-class-II-antigen positive melanoma cells presenting peptide in vitro. Cancer Immunol Immunother 2000; 48:621-6.
85. Curiel-Lewandrowski C, Demierre MF. Advances in specific immunotherapy of malignant melanoma. J Am Acad Dermatol 2000; 43:167-85.
86. Lugini L, Lozupone F, Matarrese P, Funaro C, Luciani F, Malorni W, et al. Potent phagocytic activity discriminates metastatic and primary human malignant melanomas: a key role of ezrin. Lab Invest 2003; 83:1555-67.
87. Lugini L, Matarrese P, Tinari A, Lozupone F, Federici C, Iessi E, et al. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res 2006; 66:3629-38.
88. Buckley KJ, Hayashi M. Lytic activity localized to membrane-spanning region of phi X174 E protein. Mol Gen Genet 1986; 204:120-5.
89. Maratea D, Young K, Young R. Deletion and fusion analysis of the phage phiX174 lysis gene E. Gene 1985; 40:39-46.
90. Pfründer H, Amidjojo M, Kragl U, Weuster-Botz D. Efficient whole-cell biotransformation in a biphasic ionic liquid/water system. Angew Chem Int Ed 2004; 43:4529-31.
91. Pfründer H, Jones R, Weuster-Botz D. Water immiscible ionic liquids as solvents for whole cell biocatalysis. J Biotechnol 2006; 124:182-90.
92. Yang Z, Pan W. Ionic liquids: Green solvents for nonaqueous biocatalysis. Enzyme and Microbial Technology 2005; 37:19-28.
93. Kaftzik N, Wasserscheid P, Kragl U. Use of ionic liquids to increase the yield and enzyme stability in the β-galactosidase catalysed cynthesis of n-acetyllactosamine. Org Process Res Dev 2002; 6:553-7.